Physician profile
Lewis Rose
NPI 1407923113
$1,438.39
in general payments reported to CMS, 2019-2025
14 companies · $597 in 2025
The $597 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.21 · 2021: $112 · 2022: $56.76 · 2023: $249 · 2024: $397 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.51 |
| Education | $149.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $223.20 | 2023-2025 | Imfinzi, Lynparza |
| Daiichi Sankyo INC. | $179.62 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| Astellas Pharma US INC | $174.94 | 2024-2025 | Xtandi, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $163.71 | 2023-2024 | Opdivo, Krazati, Eliquis |
| Array Biopharma INC | $126.62 | 2023-2025 | Braftovi, Lorbrena, Xalkori |
| Eisai INC. | $122.58 | 2023-2024 | |
| Gilead Sciences, INC. | $104.96 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $100.01 | 2021 | |
| Novartis Pharmaceuticals Corporation | $84.03 | 2022-2024 | |
| Celgene Corporation | $59.74 | 2025 | Reblozyl |
| Pfizer INC. | $35.80 | 2025 | |
| Amgen INC. | $27.21 | 2019 | |
| Adc Therapeutics America, INC. | $19.79 | 2025 | |
| Genentech USA, INC. | $16.18 | 2023 | Phesgo, Perjeta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.